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NEW THERAPEUTIC TARGET IDENTIFIED FOR LEIGH SYNDROME
BY JAMIE TALAN
S
cientists at the University of Washington in Seattle who are studying the rapamycin (mTOR) signaling pathway and its impact on the aging process have made a serendipitous discovery that could have an impact on people born with a Leigh syndrome, the most common (and lethal) mitochondrial disorder.
Reporting in the Nov. 14 online edition of Science, they suggest that targeting the mTOR pathway could be one way of treating the condition. At present, there are no treatments for Leigh syndrome. In theory, the finding could also lead to treatments for other mitochondrial conditions. The study's senior author, Matt Kaeberlein, PhD, a biologist and associate professor of pathology, is best known for his work with caloric restriction, showing that inhibiting the mTOR pathway kicks into gear the same events that take place with curbing calories; both can increase lifespan in mice -by ten to 15 percent in T racy Dixon-Salazar, PhD , held her audience captive last October when she took to the lectern for a featured plenary at the American Neurological Association annual meeting. The associ-• ate research director at Citizens United for Research in Epilepsy ( CURE) had come to talk about her research at the University of California, San Diego (UCSD) , which had led to the identification of gene abnormalities in a patient with Lennox-Gastaut syndrome, a form of epilepsy that starts in childhood. And she had encouraging news -treatment with a calcium-channel blocker had reduced seizures in that patient from 300 a month to 20. Four cardlOVSscular deaths, including three sudden deaths, and one myocardial infarction in a patient with a history of hyperlipidemia and hypertension were reported among approximately 2600 patients exposed lo AUBAGfO in the premarketing database. These cardiovascular deaths occuried during uncontrolled extension studies, one lo nine years after initiation of treatment.
A relaUonship between terinunomide and cardiovascular death has not been established.
Hypophosphatemia
In clinical trials, 18% of teriflunomide-treated subjects had mild hypophosphalemia (~ 0.6 mmoVL and < lower limtt of normal), compared to 9% of placebo-treated subjects; 5% of lerillunomide-lreated subjects had moderate hypophosphatemia (<?0.3 mmoVL and <0.6 mmoV L), compared to 1% of placebo-treated subjects. No subject in either treatment group had a serum phosphorus <0.3 mmolil.
DRUG INTERACTIONS Effect of teriftunomide on CYP2CB substrates
There was an increase in mean repaglinide Cmax and AUC (1.7-and 2.4-fold, respectively), lollowing repeated doses of teriflunomide and a single dose of 0.25 mg repaglinide, suggesting that teriftunomide is an inhibitor ol CYP2C8 in vivo. The magnitude of interaction could be higher at the recommended repaglinide dose. Therefore, monitoring patients with concomitant use of drugs metabolized by CYP2C8, such as repaglinide, paclitaxel, pioglitazone, or rosiglitazone is recommended as they may have higher exposure. Effect of teriflunomide on warfarin A 25% decrease in peak international normalized ratio (INR) was observed when leriflunomide was coadministered with wartarin as compared with warlarin alone. Therefore, when wartarin is coadministered wtth teriflunomide, close INR follow-up and monitoring is recommended.
Effect of teriflunomide on oral contraceptives
There was an increase in mean ethinylestradiol Cmax and AUC0-24 (1.58-and 1.54-fold, respectively) and levonorgestrel Cmax and AUC0-24 (1.33-and 1.41-fold, respectively) following repeated doses of teriflunomide. Consideration should be given to the type or dose of oral contraceptives used in combination with teriflunomide.
Effect of teriflunomide on CYP1A2 substrates
Repeated doses of teriflunomide decreased mean Cmax and AUG of caffeine (CYP1 A2 substrate) by t8% and 55% respectively, suggesting that teriflunomide may be in vivo a weak inducer of CYP1A2. Therefore, patients should be monitored when teriflunomide is coadministered with drugs metabolized by CYP1 A2 (such as duloxetine, alosetron, theophylline and tizanidine), as the efficacy of such drugs could be reduced. ' 8.
USE IN SPECIFIC POPULATIONS 8.1 Pregnancy Pregnancy Category X [see Contraindications /4.2) and Warnings and Precautions /5.2)]
When teriflunomide (oral doses of 1, 3, or 10 mg/kg/day) was administered to pregnant rats th roughout the period of organogenesis, high incidences of fetal malformation (primarily craniolacial, and axial and appendicular skeletal detects) and embryoletal death were observed at doses not associated with maternal toxicity. Adverse effects on embryofetal development were observed following dosing at vanous stages throughout organogenesis. Maternal plasma exposure at the no-effect level (1.0 mg/kg/day) for embryofetal developmental toxicity in rats was less than that in humans at the maximum recommended human dose (M RHD, 14 mg /day).
AUBAGIO® (teriflunomide) tablets for oral administration
Administration of lermunomide (oral doses of 1, 3.5 or t 2 mg/kg/day) to pregnant rabbfts lhroughoul organogenesis resutted in high incidences of felal malfOlll1ation (primanly cranlolacial, and axial and appeooicular skelelal defects) and embl}'ofetal death al doses associated with minimal maternal toxicity. Maternal plasma exposure al the no-effect dose (1.0 mgll<g.fi'lay) for em~felal developmental toxicity in rabbits was less than lhat in humans at lhe MRHO.
In studies In which teriflunomlde {oral doses ol 0.05, 0. 1, 0.3, 0.6, or 1.0 rr¢glday) was administered to ralS during gestation and lactation, deaeased growth, eye and skin abnormanties, and high incidences ol malfollll1cltlon (fimb defects) and postnatal death were observed iri lhe offspring al doses not associated with maternal toxicity. Maternal plasma exposure at lhe no-effect dose for pre-and poslnalal developmenlal toxicity in rats (0.10 mglkwday) was less than !hat in humans at the MRHD. In animal reproduction studies of lefiunomide, embryolelhalily and teratogenic effects were observed in pregnant rat and rabbit al or below clinical~ relevant plasma leriflunomide exposures (AUC). In published reproduclion studies in pregnant mice, lellunomlde was ernbryolethal and increased the incidence of mafformallons (craniOfacial, axial skeletal, heart and great vessel). Supplementation with exogenous uridine reduced lhe teratogenio effecls in pregnant m1 ce, suggesting !hat the mode of action ~nhibition of mftochondrial enzyme dihydroorotate dehydrogenase) is lhe same for therapeutk efficacy and developmental toxicity.
At cecornmended <loses in humans, teriflunomlde and leflunomlde result tn a similar range of plasma concentrations of teriflunomide. Use in Males AUBAGIO is detected in human semen. Animal studies to specifically evaluate the risk of male-mediated fetal toxicity have not been conducted. To m1rumize any possible risk, men not wishing lo father a child and their female partners should use reliable contraception. Men wishing to father a child should discontinue use of AUBAGIO and undergo an accelerated elimination procedure to decrease lhe plasma concenlration ol leriflunomide lo less than 0.02 mg.it (0.02 mcg.lml) [see W?mings and Precautions (5.3A, Pregnancy Regfslr, Allhou~h AUBAGIO Is contraindicated In pregnancy, a pregriancy registry has been established to morutor felal outcomes of pregnant women exposed lo AUBAGIO. Physicians are encouraged to enroU pregnant women ln the AUBAGIO pregnancy registl}', or pregnant women may enroll themselves, by calling 1-800-745-4447, option 2.
Nursing Mothers
Terillunomide was detected in rat milk following a single oral dose of teriflunomide. It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from AUBAGIO a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug lo the mother. Teriflunomide 70 mg dai~ up lo 14 days was well tolerated by healthy subjects.
Pediatric Use
In the event of clinical~ significant overdose or toxicity, cholestyramine or activated charcoal is Proceedings of the National Academy of Sciences that these were developmental changes and could portend vulnerability to the disease. They went on to extend their findings in post-mortem brain tissue from young adults.
Dr. Reiman met members of the Brown's Advanced Baby Imaging Laboratory during a visit to Brown . They were con ducting neurodevelopment studies on normal infants and young children. He asked if his Arizona colleagues could characterize the children's APOE genotypes and work with them to compare brain images in the APOE4 carriers and non-carrier groups.
"Our findings raise more questions than answers," said Dr. Reiman. "Additional studies are needed to clarify the neurodevelopmental processes affected by APOE variants, the extent to which these or other neurodevelopmental processes provide a foothold for the pathogenesis of Alzheimer's in older adults, and the extent to which these processes could be targeted in the discovery of treatments to prevent this disease."
While it is impossible to know the underlying substrates responsible for these brain differences, Dr. Reiman has some thoughts about the mechanism. APOE is involved in cholesterol transport and cholesterol is implicated in brain development and myelination. It's also possible that APOE is involved in white matter myelination, maintaining and repairing myelin and the E4 allele make the system less efficient, Dr. Deoni added.
One of the lead authors of the study, Douglas C. Dean lll, PhD, ofBrown University' s School of Engineering, heads up the ongoing study of normal development at Brown' s Advanced Baby Imaging
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Continued from page 17 lab. The investigators have recruited around 400 children, and now have amassed" information from 700 brain scans. They have mined the data to study the role of breastfeeding on early brain development, are studying language acquisition, and are conducting a broad range of cognitive and behavioral assessments on the children over time.
" John C. Morris, MD, director of the Charles F. andJoanne Knight Alzheimer's Disease Research Center at Washington University, noted that the study authors were careful to call the findings preliminary. "It is provocative," he said. "It will be important for future studies to extend this finding and try to understand its relationship to the genetic factors at ' work in Alzheimer's." "Studies have shown that adults with APOE4 have metabolic changes. This [study] pushes things back even further and says that APOE4 as a risk factor may be operating over a lifetime," said Dr. Morris. "We are interested in genetic risk factors and how these risk factors interact with the greatest AD risk factor of all -aging."
"There are clearly differences in brain function in E4 carriers," said John Hardy, PhD, a professor of neuroscience demands of any brain region. But this is utter speculation."
It will be important for colleagues to figure out the links between APOE4, development, aging and AD, Dr. Knopman said. Still, he added, "hypometabolic changes probably do constitute a risk for AD," and investigators will need to figure out what APOE4 is doing to cause changes in the brains of young children. 
